LiPlasome Pharma ApS

LiPlasome is a Danish privately owned biotech company focusing on oncology.
The LiPlasome technology provides a liplasomal reformulation of the most used anticancer drugs on the market like
Cispaltin -> LiPlaCis® and Oxaliplatin -> LiPloxa.

The aim is to provide more effective treatment to cancer patients with fewer side effects.

LiPlasomes most advanced program is LiPlaCis® in a close escalating clinical phase 1 trial. Please see clinicaltrials.gov.

A screening program to select “high likelihood responding patients” to be included in extension phase 1/phase 2 has been initiated.
LiPloxa is the most advanced pre-clinical program.

LiPlasome Pharma ApS
Venlighedsvej 1
DK-2970 Hoersholm
Tel: +45 72 15 20 20
Mail: info@liplasome.com

CEO
Peter Buhl Jensen

COO
Mogens Winkel Madsen